… Results suggest a therapeutic benefit for EGFR blockade with erlotinib in patients with
biliary cancer. Additional studies with erlotinib as a single agent and in combination with other …

… large randomized studies that investigated erlotinib or gefitinib in … We did a phase II study of
single-agent erlotinib as first-line … studies on tumor samples of patients entered in the study to …

Introduction: Erlotinib improves survival in patients with advanced non-small cell lung
cancer who have been previously treated with systemic chemotherapy. The current trial was …

… This phase II study of erlotinib in patients with metastatic colorectal cancer was … of the study
were (1) to assess the efficacy (response rate and duration of stable disease (sd)) of erlotinib …

… nia in both studies.We conducted this international, randomized phase II trial to prospectively
compare the progression-free survival (PFS) of erlotinib plus tivantinib with erlotinib plus …

… the relative efficacy of erlotinib and gefitinib in patients with advanced NSCLC and BM. In
a recently published randomized phase II study of erlotinib versus gefitinib in patients with …

… contribute to the benefit observed with sequential erlotinib in this study. Indeed, two patients
with EGFR mutations obtained a substantial benefit with sequential erlotinib (PFS, 56 to 82+ …

… on the BR-21 trial, the number of patients treated on the current study was small, and the …
, Phase II study. We do not believe that further testing of single-agent erlotinib administered at …

… One-hundred fifteen patients were enrolled onto this study. Forty-seven percent of patients
received erlotinib at 150 mg daily throughout the entire study, 6% had dose escalations, and …

… of a phase II study of the efficacy and safety of erlotinib in Japanese patients with relapsed or
recurrent advanced NSCLC. The study … erlotinib, and a biomarker analysis was conducted. …